Upexi (UPXI) Competitors $3.26 +0.38 (+12.98%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$3.26 -0.01 (-0.31%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock UPXI vs. FULC, ITOS, RVNC, ETON, RZLT, CYRX, ERAS, VIGL, CKPT, and TECXShould you be buying Upexi stock or one of its competitors? The main competitors of Upexi include Fulcrum Therapeutics (FULC), iTeos Therapeutics (ITOS), Revance Therapeutics (RVNC), Eton Pharmaceuticals (ETON), Rezolute (RZLT), CryoPort (CYRX), Erasca (ERAS), Vigil Neuroscience (VIGL), Checkpoint Therapeutics (CKPT), and Tectonic Therapeutic (TECX). These companies are all part of the "pharmaceutical products" industry. Upexi vs. Its Competitors Fulcrum Therapeutics iTeos Therapeutics Revance Therapeutics Eton Pharmaceuticals Rezolute CryoPort Erasca Vigil Neuroscience Checkpoint Therapeutics Tectonic Therapeutic Fulcrum Therapeutics (NASDAQ:FULC) and Upexi (NASDAQ:UPXI) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk. Which has better valuation & earnings, FULC or UPXI? Fulcrum Therapeutics has higher revenue and earnings than Upexi. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFulcrum Therapeutics$80M4.73-$9.73M-$0.07-100.06Upexi$16.56M7.47-$23.66MN/AN/A Do analysts rate FULC or UPXI? Fulcrum Therapeutics currently has a consensus price target of $6.29, suggesting a potential downside of 10.26%. Upexi has a consensus price target of $16.00, suggesting a potential upside of 390.05%. Given Upexi's stronger consensus rating and higher possible upside, analysts clearly believe Upexi is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fulcrum Therapeutics 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.50Upexi 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor FULC or UPXI? In the previous week, Upexi had 1 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 3 mentions for Upexi and 2 mentions for Fulcrum Therapeutics. Upexi's average media sentiment score of 0.73 beat Fulcrum Therapeutics' score of -0.32 indicating that Upexi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Upexi 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, FULC or UPXI? Fulcrum Therapeutics has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500. Comparatively, Upexi has a beta of -0.58, suggesting that its stock price is 158% less volatile than the S&P 500. Is FULC or UPXI more profitable? Fulcrum Therapeutics has a net margin of 0.00% compared to Upexi's net margin of -135.86%. Fulcrum Therapeutics' return on equity of -0.20% beat Upexi's return on equity.Company Net Margins Return on Equity Return on Assets Fulcrum TherapeuticsN/A -0.20% -0.19% Upexi -135.86%-535.19%-122.94% Do insiders and institutionals hold more shares of FULC or UPXI? 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Upexi shares are owned by institutional investors. 7.0% of Fulcrum Therapeutics shares are owned by insiders. Comparatively, 31.6% of Upexi shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryFulcrum Therapeutics beats Upexi on 9 of the 15 factors compared between the two stocks. Get Upexi News Delivered to You Automatically Sign up to receive the latest news and ratings for UPXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UPXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPXI vs. The Competition Export to ExcelMetricUpexiTechnology Services IndustryBusiness SectorNASDAQ ExchangeMarket Cap$123.79M$2.40B$13.04B$9.02BDividend YieldN/A1.34%2.56%4.10%P/E RatioN/A31.6828.7920.28Price / Sales7.4735.9442.34121.46Price / CashN/A40.7025.6857.47Price / Book0.525.876.285.68Net Income-$23.66M$32.32M$187.97M$248.96M7 Day Performance25.58%5.99%3.56%3.30%1 Month Performance-70.93%7.19%4.15%5.20%1 Year Performance-59.97%32.79%27.98%21.37% Upexi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPXIUpexi3.4862 of 5 stars$3.27+13.0%$16.00+390.0%-60.0%$123.79M$16.56M0.00130Upcoming EarningsGap UpHigh Trading VolumeFULCFulcrum Therapeutics0.3447 of 5 stars$6.88-3.1%$6.29-8.6%+13.8%$383.25M$80M-98.27100ITOSiTeos Therapeutics3.2101 of 5 stars$9.97+0.2%$15.86+59.0%-31.2%$381.59M$35M-3.2890RVNCRevance Therapeutics2.8093 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500ETONEton Pharmaceuticals2.539 of 5 stars$14.25+1.7%$29.67+108.2%+341.5%$375.72M$48.33M-79.1720RZLTRezolute3.0399 of 5 stars$4.46+2.5%$11.83+165.3%+14.5%$372.01MN/A-3.8840High Trading VolumeCYRXCryoPort1.9688 of 5 stars$7.46+0.7%$11.00+47.5%+22.0%$371.52M$228.38M-3.191,186ERASErasca3.1003 of 5 stars$1.27-3.1%$4.57+260.0%-36.7%$371.11MN/A-2.05120VIGLVigil Neuroscience3.3678 of 5 stars$7.95flat$10.80+35.8%+102.3%$371.04MN/A-3.8840CKPTCheckpoint Therapeutics0.5091 of 5 stars$4.26flat$4.33+1.7%N/A$370.71M$41K-2.3210TECXTectonic Therapeutic3.6303 of 5 stars$19.87+0.4%$83.60+320.7%+38.6%$369.72MN/A-2.72120 Related Companies and Tools Related Companies FULC Alternatives ITOS Alternatives RVNC Alternatives ETON Alternatives RZLT Alternatives CYRX Alternatives ERAS Alternatives VIGL Alternatives CKPT Alternatives TECX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UPXI) was last updated on 7/4/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredHave you heard of “E.I.”?Inside Expert: New "E.I." Tech Could Be Poised For 200,000% Growth Meta, Apple, and even NASA are rushing t...Behind the Markets | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upexi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upexi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UPXI Stock Alerts